The efficacy of intravenous Labetalol on pain controlling and anxiety during bone marrow aspiration and biopsy

Comparison of the efficacy of intravenous Labetalol and the usual method (local anesthesia) on pain controlling and anxiety during bone marrow aspiration and biopsy

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191201045563N1

Enrollment

Registered

2020-01-05

Start date

2019-12-06

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Marrow Aspiration and Biopsy.

Interventions

Intervention 1: Intervention group: Patients in the intervention group will receive IV labetalol (5mg) in addition to fentanyl and anesthesia. Intervention 2: Control group: Patients in the control gr

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age more than 18 years old Definitive indication of bone marrow aspiration and biopsy

Exclusion criteria

Exclusion criteria: Unwillingness to participate in the study Cardiovascular disease (Heart block, Arrhythmia) Uncontrolled chronic obstructive pulmonary disease Uncontrolled Asthma Unstable hemodynamics especially hypotension, bradycardia Consciousness disorder Pregnancy and lactation Bad physical conditions Using analgesic agents for the past 24 hours Elderly people with advanced systemic disease Vertigo, headache, dyspnea, nausea before the procedure

Design outcomes

Primary

Measure	Time frame
Pain intensity based on 10cm visual analogue scale(VAS). Timepoint: During the procedure, 5 minutes and one hour after the procedure. Method of measurement: 10cm visual analogue scale (VAS).	—

Secondary

Measure	Time frame
Anxiety score. Timepoint: 30 minutes before starting the procedure and during the procedure. Method of measurement: Clinical Anxiety-Depression Self-Assessment Scale (HADS).;Amount of opioids used during the procedure and within 24 hours after the procedure. Timepoint: During the procedure, up to 24 hours after the procedure. Method of measurement: Record the amount of drug used in each patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoudeh Darzi

Semnan University of Medical Sciences

MasoudehDarzi@semums.ac.ir+98 23 3142 2120

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026